cognitive decline: systematic review and meta-analysis. *Stroke* 2020; 51: 2374–2385.

74. Kim BJ, Kwon SU, Kim Y-H, et al. White matter lesion volume change and antiplatelet treatment in small vessel disease: quantitative analysis from PICASSO Study (Abstract TP512). *Stroke* 2019; 50: ATP512–ATP512.

75. Kim BJ, Kwon SU, Park JH, et al. Cilostazol versus aspirin in ischaemic stroke patients with high-risk cerebral hemorrhage: Subgroup analysis of the PICASSO trial. *Stroke* 2020; 51: 931–937.

76. McNeil JJ, Wolfe R, Woods RL, et al. Effect of aspirin on cardiovascular events and bleeding in the healthy elderly. *N Engl J Med* 2018; 379: 1509–1518.

77. McNeil JJ, Woods RL, Nelson MR, et al. Effect of aspirin on disability-free survival in the healthy elderly. *N Engl J Med* 2018; 379: 1499–1508.

78. McNeil JJ, Nelson MR, Woods RL, et al. Effect of aspirin on all-cause mortality in the healthy elderly. *N Engl J Med* 2018; 379: 1519–1528.

79. Holcombe A, Ammann E, Espeland MA, et al. Chronic use of aspirin and total white matter lesion volume: results from the Women's Health Initiative Memory Study of Magnetic Resonance Imaging Study. *J Stroke Cerebrovasc Dis* 2017; 26: 2128–2136.

80. Han HJ, Kim BC, Youn YC, et al. A comparison study of cilostazol and aspirin on changes in volume of cerebral small vessel disease white matter changes: protocol of a multicenter, randomized controlled trial. *Dement Neurocogn Disord* 2019; 18: 138–148.

81. Reid CM, Storey E, Wong TY, et al. Aspirin for the prevention of cognitive decline in the elderly: rationale and design of a neuro-vascular imaging study (ENVISION). *BMC Neurol* 2012; 12: 3.

82. Ward SA, Storey E, Woods RL, et al. The study of neurocognitive outcomes, radiological and retinal effects of aspirin in sleep apnoea – rationale and methodology of the SNORE-ASA study. *Contemp Clin Trials* 2018; 64: 101–111.

83. Wardlaw J, Bath PMW, Doubal F, et al. Protocol: the Lacunar Intervention Trial 2 (LACI-2). A trial of two repurposed licenced drugs to prevent progression of cerebral small vessel disease. *Eur Stroke J* 2020; 5: 297–308.

84. Saito S, Kojima S, Oishi N, et al. A multicenter, randomized, placebo-controlled trial for cilostazol in patients with mild cognitive impairment: the COMCID study protocol. *Alzheimer's Dementia (New York, N Y)* 2016; 2: 250–257.

85. Intercollegiate Stroke Working Party. *National clinical guideline for stroke*. Report no. 5th ed. London: Author, 2016.

86. Kernan WN, Ovbiagele B, Black HR, et al. Guidelines for the prevention of stroke in patients with stroke and transient ischaemic attack: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. *Stroke* 2014; 45: 2160–2236.

87. Wardlaw JM, Smith C and Dichgans M. Small vessel disease: mechanisms and clinical implications. *Lancet Neurol* 2019; 18: 684–696.

88. Mok VC, Lam WW, Fan YH, et al. Effects of statins on the progression of cerebral white matter lesion: post hoc analysis of the ROCAS (Regression of Cerebral Artery Stenosis) study. *J Neurol* 2009; 256: 750–757.

89. Fu JH, Mok V, Lam W, et al. Effects of statins on progression of subclinical brain infarct. *Cerebrovasc Dis* 2010; 30: 51–56.

90. Guo Y, Li Y, Liu X, et al. Assessing the effectiveness of statin therapy for alleviating cerebral small vessel disease progression in people ≥75 years of age. *BMC Geriatr* 2020; 20: 1–13.

91. Ji T, Zhao Y, Wang J, et al. Effect of low-dose statins and apolipoprotein E Genotype on cerebral small vessel disease in older hypertensive patients: a subgroup analysis of a randomized clinical trial. *J Am Med Direct Assoc* 2018; 19: 995–1002.e1004.

92. Zhang J, Liu N and Yang C. Effects of rosuvastatin in combination with nimodipine in patients with mild cognitive impairment caused by cerebral small vessel disease. *Panminerva Medica* 2019; 61: 439–443.

93. ten Dam VH, van den Heuvel DM, van Buchem MA, et al. Effect of pravastatin on cerebral infarcts and white matter lesions. *Neurology* 2005; 64: 1807–1809.

94. Ramanan VK, Przybelski SA, Graff-Radford J, et al. Statins and Brain Health: Alzheimer's disease and cerebrovascular disease biomarkers in older adults. *J Alzheimer's Dis* 2018; 65: 1345–1352.

95. Gyanwali B, Shaik MA, Tan BY, et al. Risk factors for and clinical relevance of incident and progression of cerebral small vessel disease markers in an Asian memory clinic population. *J Alzheimer's Dis* 2019; 67: 1209–1219.

96. Wan X, Wang W, Liu J, et al. Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range. *BMC Med Res Methodol* 2014; 14: 1–13.

97. Appleton JP, Scutt P, Sprigg N, et al. Hypercholesterolaemia and vascular dementia. *Clin Sci* 2017; 131: 1561–1578.

98. Mortensen MB and Falk E. Primary prevention with statins in the elderly. *J Am Coll Cardiol* 2018; 71: 85–94.

99. Cholesterol Treatment Trialists Collaboration. Efficacy and safety of statin therapy in older people: a meta-analysis of individual participant data from 28 randomised controlled trials. *Lancet* 2019; 393: 407–415.

100. Gencer B, Marston NA, Im K, et al. Efficacy and safety of lowering LDL cholesterol in older patients: a systematic review and meta-analysis of randomised controlled trials. *Lancet* 2020; 396: 1637–1643.

101. Meschia JF, Bushnell C, Boden-Albala B, et al. Guidelines for the primary prevention of stroke: a statement for healthcare professionals from the American Heart Association/American Stroke Association. *Stroke* 2014; 45: 3754–3832.

102. Arnett DK, Blumenthal RS, Albert MA, et al. 2019 ACC/AHA guideline on the primary prevention of
cardiovascular disease: Executive Summary: A report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. *Circulation* 2019; 140: e563–e595.

103. WHO Guidelines Approved by the Guidelines Review Committee. *Risk reduction of cognitive decline and dementia: WHO Guidelines*. Geneva: World Health Organization, https://www.who.int/mental_health/neurology/dementia/guidelines_risk_reduction/en/ (2019)

104. Landman TR, Thijssen DH, Tuladhar AM, et al. Relation between physical activity and cerebral small vessel disease: a nine-year prospective cohort study. *Int J Stroke* 2021; 16: 1747493020984090.

105. Liu-Ambrose T, Best JR, Davis JC, et al. Aerobic exercise and vascular cognitive impairment: a randomized controlled trial. *Neurology* 2016; 87: 2082–2090.

106. Hsu CL, Best JR, Davis JC, et al. Aerobic exercise promotes executive functions and impacts functional neural activity among older adults with vascular cognitive impairment. *Br J Sports Med* 2018; 52: 184–191.

107. Wong A, Mak MKY, Lam LCW, et al. Aerobic dance for cognitive and physical functions and mood in older adults with cerebral small vessel disease: abridged secondary publication. *Hong Kong Med J* 2020; 26 Suppl 6: 38–41.

108. Verdelho A, Madureira S, Ferro JM, et al. Physical activity prevents progression for cognitive impairment and vascular dementia: results from the LADIS (Leukoaraiosis and Disability) study. *Stroke* 2012; 43: 3331–3335.

109. Frederiksen KS, Verdelho A, Madureira S, et al. Physical activity in the elderly is associated with improved executive function and processing speed: the LADIS Study. *Int J Geriatr Psychiatry* 2015; 30: 744–750.

110. Tang Y, Xing Y, Zhu Z, et al. The effects of 7-week cognitive training in patients with vascular cognitive impairment, no dementia (the Cog-VACCINE study): A randomized controlled trial. *Alzheimers Dementia* 2019; 15: 605–614.

111. Bowman GL, Silbert LC, Dodge HH, et al. Randomized trial of marine n-3 polyunsaturated fatty acids for the prevention of cerebral small vessel disease and Inflammation in Aging (PUFA Trial): rationale, design and baseline results. *Nutrients* 2019; 11: 735.

112. Wang J, Liu S, Zhao C, et al. Effects of trazodone on sleep quality and cognitive function in arteriosclerotic cerebral small vessel disease comorbid with chronic insomnia. *Front Psychiatry* 2020; 11: 620.

113. Stuckenschneider T, Sanders ML, Devenney KE, et al. NeuroExercise: the effect of a 12-month exercise intervention on cognition in mild cognitive impairment – a multicenter randomized controlled trial. *Front Aging Neurosci* 2020; 12: 621947.

114. Venkatraman VK, Sanderson A, Cox KL, et al. Effect of a 24-month physical activity program on brain changes in older adults at risk of Alzheimer's disease: the AIBL active trial. *Neurobiol Aging* 2020; 89: 132–141.

115. Ngandu T, Lehtisalo J, Solomon A, et al. A 2 year multidomain intervention of diet, exercise, cognitive training, and vascular risk monitoring versus control to prevent cognitive decline in at-risk elderly people (FINGER): a randomised controlled trial. *Lancet* 2015; 385: 2255–2263.

116. Teuschl Y, Ihle-Hansen H, Matz K, et al. Multidomain intervention for the prevention of cognitive decline after stroke – a pooled patient-level data analysis. *Eur J Neurol* 2018; 25: 1182–1188.

117. Verdelho A, Madureira S, Correia M, et al. Impact of physical activity in vascular cognitive impairment (AFIVASC): study protocol for a randomised controlled trial. *Trials* 2019; 20: 114.

118. Willey JZ, Moon YP, Paik MC, et al. Lower prevalence of silent brain infarcts in the physically active: the Northern Manhattan Study. *Neurology* 2011; 76: 2112–2118.

119. Moniruzzaman M, Kadota A, Segawa H, et al. Relationship between step counts and cerebral small vessel disease in Japanese men. *Stroke* 2020; 51: 3584–3591.

120. English C, MacDonald-Wicks L, Patterson A, et al. The role of diet in secondary stroke prevention. *Lancet Neurol* 2021; 20: 150–160.

121. Martí-Carvajal AJ, Solà I, Lathyris D, et al. Homocysteine-lowering interventions for preventing cardiovascular events. *Cochrane Database Syst Rev* 2017; 8: Cd006612.

122. Al-Khudairy L, Flowers N, Wheelhouse R, et al. Vitamin C supplementation for the primary prevention of cardiovascular disease. *Cochrane Database Syst Rev* 2017; 3: Cd011114.

123. Hooper L, Al-Khudairy L, Abdelhamid AS, et al. Omega-6 fats for the primary and secondary prevention of cardiovascular disease. *Cochrane Database Syst Rev* 2018; 7: Cd011094.

124. Gons RA, van Norden AG, de Laat KF, et al. Cigarette smoking is associated with reduced microstructural integrity of cerebral white matter. *Brain* 2011; 134: 2116–2124.

125. Madsen KS, Kähler P, Kähler LKA, et al. Metformin and second-or third-generation sulphonylurea combination therapy for adults with type 2 diabetes mellitus. *Cochrane Database Syst Rev* 2019; 2019: CD012368.

126. Launer LJ, Miller ME, Williamson JD, et al. Effects of intensive glucose lowering on brain structure and function in people with type 2 diabetes (ACCORD MIND): a randomised open-label substudy. *Lancet Neurol* 2011; 10: 969–977.

127. Wang D-Q, Wang L, Wei M-M, et al. Relationship between type 2 diabetes and white matter hyperintensity: a systematic review. *Front Endocrinol* 2020; 11: 595962.

128. van Agtmaal MJM, Houben A, de Wit V, et al. Prediabetes is associated with structural brain abnormalities: the Maastricht Study. *Diabetes Care* 2018; 41: 2535–2543.

129. Groeneveld ON, Moneti C, Heinen R, et al. The clinical phenotype of vascular cognitive impairment in patients
with type 2 diabetes Mellitus. *J Alzheimer's Dis* 2019; 68: 311–322.

130. Schneider ALC, Selvin E, Sharrett AR, et al. Diabetes, prediabetes, and brain volumes and subclinical cerebrovascular disease on MRI: The Atherosclerosis Risk in Communities Neurocognitive Study (ARIC-NCS). *Diabetes Care* 2017; 40: 1514–1521.

131. Reitz C, Guzman VA, Narkhede A, et al. Relation of dysglycemia to structural brain changes in a multiethnic elderly cohort. *J Am Geriatr Soc* 2017; 65: 277–285.

132. Raffield LM, Cox AJ, Freedman BI, et al. Analysis of the relationships between type 2 diabetes status, glycemic control, and neuroimaging measures in the Diabetes Heart Study Mind. *Acta Diabetol* 2016; 53: 439–447.

133. Bryan RN, Bilello M, Davatzikos C, et al. Effect of diabetes on brain structure: the action to control cardiovascular risk in diabetes MR imaging baseline data. *Radiology* 2014; 272: 210–216.

134. Tamura Y, Kimbara Y, Yamaoka T, et al. White matter hyperintensity in elderly patients with diabetes mellitus is associated with cognitive impairment, functional disability, and a high glycoalbumin/glycohemoglobin ratio. *Front Aging Neurosci* 2017; 9: 220.

135. Sudre CH, Smith L, Atkinson D, et al. Cardiovascular risk factors and white matter hyperintensities: difference in susceptibility in south Asians compared with Europeans. *J Am Heart Assoc* 2018; 7: e010533.

136. Weinstein G, Davis-Plourde KL, Conner S, et al. Association of metformin, sulfonylurea and insulin use with brain structure and function and risk of dementia and Alzheimer's disease: pooled analysis from 5 cohorts. *PloS one* 2019; 14: e0212293.

137. American Diabetes Association. 6. Glycemic targets: standards of medical care in diabetes – 2021. *Diabetes Care* 2021; 44: S73–S84.

138. Hampel H, Mesulam MM, Cuello AC, et al. The cholinergic system in the pathophysiology and treatment of Alzheimer's disease. *Brain* 2018; 141: 1917–1933.

139. Folch J, Busquets O, Ettcheto M, et al. Memantine for the treatment of dementia: a review on its current and future applications. *J Alzheimers Dis* 2018; 62: 1223–1240.

140. Tohgi H, Abe T, Kimura M, et al. Cerebrospinal fluid acetylcholine and choline in vascular dementia of Binswanger and multiple small infarct types as compared with Alzheimer-type dementia. *J Neural Transm (Vienna)* 1996; 103: 1211–1220.

141. Bès A, Orgogozo JM, Poncet M, et al. A 24-month, double-blind, placebo-controlled multicentre pilot study of the efficacy and safety of nicergoline 60 mg per day in elderly hypertensive patients with leukoaraiosis. *Eur J Neurol* 1999; 6: 313–322.

142. Battle CE, Abdul-Rahim AH, Shenkin SD, et al. Cholinesterase inhibitors for vascular dementia and other vascular cognitive impairments: a network meta-analysis. *Cochrane Datab Syst Rev* 2019; 2019: CD013306.

143. Dichgans M, Markus HS, Salloway S, et al. Donepezil in patients with subcortical vascular cognitive

impairment: a randomised double-blind trial in CADASIL. *Lancet Neurol* 2008; 7: 310–318.

144. McShane R, Westby MJ, Roberts E, et al. Memantine for dementia. *Cochrane Datab Syst Rev* 2019. DOI: 10.1002/14651858.CD003154.pub6.

145. Peng D, Geriatric Neurology Group CSoG and Group CPGfCIoCSVDW. Clinical practice guideline for cognitive impairment of cerebral small vessel disease. *Aging Med* 2019; 2: 64–73.

146. Jia J, Wei C, Liang J, et al. The effects of DL-3-n-butylphthalide in patients with vascular cognitive impairment without dementia caused by subcortical ischaemic small vessel disease: a multicentre, randomized, double-blind, placebo-controlled trial. *Alzheimers Dement* 2016; 12: 89–99.

147. Demarin V, Kes VB, Trkanjec Z, et al. Efficacy and safety of Ginkgo biloba standardized extract in the treatment of vascular cognitive impairment: a randomized, double-blind, placebo-controlled clinical trial. *Neuropsychiatr Dis Treat* 2017; 13: 483–490.

148. Fioravanti M and Yanagi M. Cytidinediphosphocholine (CDP-choline) for cognitive and behavioural disturbances associated with chronic cerebral disorders in the elderly. *Cochrane Datab Syst Rev* 2005. DOI: 10.1002/14651858.CD000269.pub3.

149. Cotroneo AM, Castagna A, Putignano S, et al. Effectiveness and safety of citicoline in mild vascular cognitive impairment: the IDEALE study. *Clin Interv Aging* 2013; 8: 131–137.

150. Birks J and Evans JG. Ginkgo biloba for cognitive impairment and dementia. *Cochrane Datab Syst Rev* 2009. DOI: 10.1002/14651858.CD003120.pub3.

151. Tan M-S, Yu J-T, Tan C-C, et al. Efficacy and adverse effects of Ginkgo Biloba for cognitive impairment and dementia: a systematic review and meta-analysis. *J Alzheimer's Dis* 2015; 43: 589–603.

152. Cui S, Chen N, Yang M, et al. Cerebrolysin for vascular dementia. *Cochrane Datab Syst Rev* 2019; 2019: CD008900.

153. Hao Z, Liu M, Liu Z, et al. Huperzine A for vascular dementia. *Cochrane Datab Syst Rev* 2009; 2009: CD007365.

154. Guekht A, Skoog I, Edmundson S, et al. ARTEMIDA Trial (a randomized trial of efficacy, 12 months international double-blind Actovegin) a randomized controlled trial to assess the efficacy of Actovegin in poststroke cognitive impairment. *Stroke* 2017; 48: 1262–1270.

155. Salvadori E, Poggesi A, Donnini I, et al. Association of nimodipine and choline alphoscerate in the treatment of cognitive impairment in patients with cerebral small vessel disease: study protocol for a randomized placebo-controlled trial-the CONIVaD trial. *Aging Clin Exp Res* 2020; 32: 449–457.

156. Verdelho A, Biessels GJ, Chabriat H, et al. Cerebrovascular disease in patients with cognitive impairment: a white paper from the ESO Dementia Committee. *Eur Stroke J*. Epub ahead of print 7 February 2021. DOI: 10.1177/2396987321994294.
157. Verdelho A, Wardlaw J, Pavlovic A, et al. Cognitive impairment in patients with cerebrovascular disease: a white paper from the ESO Dementia Committee. *Eur Stroke J* 2021; 6: 23969873211000258. DOI: 10.1177/23969873211000258.

158. Ryan J, Storey E, Murray AM, et al. Randomized placebo-controlled trial of the effects of aspirin on dementia and cognitive decline. *Neurology* 2020; 95: e320–e331.

159. Patrono C and Baigent C. Role of aspirin in primary prevention of cardiovascular disease. *Nat Rev Cardiol* 2019; 16: 675–686.

160. Mortensen MB and Nordestgaard BG. Elevated LDL cholesterol and increased risk of myocardial infarction and atherosclerotic cardiovascular disease in individuals aged 70–100 years: a contemporary primary prevention cohort. *Lancet* 2020; 396: 1644–1652.

161. Brainin M, Feigin VL, Norrving B, et al. Global prevention of stroke and dementia: the WSO Declaration. *Lancet Neurol* 2020; 19: 487–488.

162. Malik R, Chauhan G, Traylor M, et al. Multiancestry genome-wide association study of 520,000 subjects identifies 32 loci associated with stroke and stroke subtypes. *Nat Genet* 2018; 50: 524–537.

163. Bath PM and Wardlaw JM. Pharmacological treatment and prevention of cerebral small vessel disease: a review of potential interventions. *Int J Stroke* 2015; 10: 469–478.

164. Chappell FM, Del Carmen Valdes Hernandez M, Makin SD, et al. Sample size considerations for trials using cerebral white matter hyperintensity progression as an intermediate outcome at 1 year after mild stroke: results of a prospective cohort study. *Trials* 2017; 18: 78.

165. Mok VC, Lam WW, Chen XY, et al. Statins for asymptomatic middle cerebral artery stenosis: The Regression of Cerebral Artery Stenosis study. *Cerebrovasc Dis* 2009; 28: 18–25.